This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.

LocationsNews & Updates
Contact Us

What can we help you find?

Top Searches

PROTAC

ADC

RNA

ADME

OLIGO

Webinars

Integrated Strategies to Accelerate Pre-Clinical Development of Antibody-Drug Conjugates

  • 12/13/2024 11am EST

  • Online Webinar

Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma.

In this GEN webinar, experts from WuXi AppTec will share essential strategies and methodologies for accelerating pre-clinical assessments of ADCs. This will include approaches for assessing the pharmacology, biotransformation, toxicokinetics, and immunogenicity of biologics early in their development. The webinar will offer methods for addressing ADC resistance as well as for metabolite profiling and identifying payload-related species for cleavable and non-cleavable ADCs.

In this webinar you'll learn:

The complex biotransformation processes of ADCs and detailed methodologies for metabolite profiling of payload-related species and Drug-to-Antibody Ratio distribution

Speaker

​Peng Li, PhD

Senior Scientist WuXi Testing-DMPK WuXi AppTec

Dr. Peng Li received his bachelor's and master’s degrees in pharmacy from China Pharmaceutical University. After earning his PhD from the University of Tuebingen, where he specialized in lipidomics and metabolomics, he joined WuXi AppTec as a principal investigator in the DMPK Service Department. Currently, he uses his extensive skills to work with exogenous metabolites in biotransformation studies in support of drug discovery and development. He is passionate about solving complex issues using mass spectrometry approach. Beyond traditional routine small molecules, his work covers different therapeutical modalities including peptides, PDCs, and ADCs.

Related Resources

Related Services and Platforms

Stay Connected

Keep up with the latest news and insights.

  • Email address*

    * Please check the filled content

  • First name*

    * Please check the filled content

  • Last name*

    * Please check the filled content

  • Company*

    * Please check the filled content

By clicking submit, you consent to WuXi AppTec DMPK collecting and processing the information you provide for our internal purposes, in accordance with our privacy policy.

* Please agree to the Privacy Policy

Submit

Thanks for signing up

Help us get to know you better! By customizing your email preferences, we can deliver curated content relevant to you.

Thanks for signing up

Help us get to know you better! By customizing your email preferences, we can deliver curated content relevant to you.